Novavax, Inc. of Gaithersburg, Maryland is continuing to move away from relying primarily on direct vaccine sales and is instead focusing more heavily on licensing agreements and corporate partnerships. The company recently expanded deals with pharmaceutical giants Pfizer, Inc. and Sanofi SA as it attempts to build a more stable revenue stream following a sharp decline in demand for COVID-19 shots.1
Company executives described the shift as part of an “amplification strategy” that centers on licensing Novavax’s vaccine technology to larger companies with broader commercial reach. The company’s Matrix-M adjuvant, a substance designed to enhance immune responses in vaccines, has become a major focus of that strategy.2
Novavax CEO John Jacobs acknowledged that independently developing and commercializing vaccines created significant financial and operational challenges for the company. Instead of managing large-scale vaccine launches on its own, Novavax now plans to rely more on outside pharmaceutical partners to handle development and distribution.3
Silvia Taylor, Novavax’s chief corporate affairs officer and head of operations in Sweden said:
The best way to increase access to our technology platform is to put it in the hands of partners, right? It’s like an amplification strategy.4
Matrix-M Technology
Matrix-M is a plant-based adjuvant designed to strengthen immune responses in vaccines. Unlike many commonly used vaccine adjuvants, it does not contain aluminum. In addition to its use in Novavax’s COVID vaccine, Matrix-M is also used in a malaria vaccine developed through a partnership between the University of Oxford in England and the Serum Institute of India.5 Independent long-term studies evaluating the adjuvant and its safety profile, however, have not yet been conducted.
In a 2023 paper published by Novavax researchers, the company stated:
The Matrix-M adjuvant consists of two distinct fractions of saponins purified from the Quillaja saponaria Molina tree, combined with cholesterol and phospholipids to form 40-nm open cage-like nanoparticles, achieving potent adjuvanticity with a favorable safety profile. Matrix-M induces early activation of innate immune cells at the injection site and in the draining lymph nodes. This translates into improved magnitude and quality of the antibody response to the antigen, broadened epitope recognition, and the induction of a Th1-dominant immune response.6
Pfizer Gains Access to Matrix-M Technology
Pfizer recently signed a licensing agreement that gives the company access to Novavax’s Matrix-M technology for up to two vaccine programs. Under the agreement, Pfizer will pay Novavax $30 million upfront, with the eligibility for milestone payments tied to product development and future sales up to $500 million.7
The deal allows Pfizer to incorporate Matrix-M into future vaccine candidates while Novavax supplies the adjuvant itself. Although the agreement provides Novavax with another source of revenue, it also reflects the company’s increasing reliance on licensing arrangements rather than sales of its own vaccine products.8
Researchers have shown increasing interest in adjuvants like Matrix-M because they may reduce the amount of vaccine material needed per dose. Pharmaceutical companies have also been looking for alternatives and additions to mRNA technology as the vaccine market becomes more competitive. Novavax’s research and development team is exploring new ways to use the adjuvant, including whether it could be combined with mRNA technology or adapted into alternative formulations such as dry powders.9
Sanofi Agreement Continues to Drive Up Revenue
Novavax is also continuing work under its partnership with Sanofi, which includes commercialization of Nuvaxovid and development of a combined COVID-flu shot. The partnership has already produced substantial milestone payments for Novavax and remains one of the company’s primary revenue drivers.10
The company has reported stronger quarterly revenue than analysts expected, though much of that income came from partnership payments and licensing activity rather than broad vaccine demand. Analysts noted that Novavax’s future growth may depend heavily on whether larger pharmaceutical companies continue investing in its technology platform.11
Industry observers say Novavax’s evolving strategy reflects wider changes in the post-pandemic vaccine market, where smaller biotech firms increasingly rely on partnerships with larger pharmaceutical companies to remain competitive and financially sustainable.12
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References:1 Liu A. With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine. Fierce Pharma Apr. 6, 2026.
2 Ibid.
3 Ibid.
4 Ibid.
5 Ibid.
6 Stertman L, Palm AKR, Zarneger B et al. The Matrix-M adjuvant: A critical component of vaccines for the 21st century. Hum Vaccin Immunother 2023; 19(1).
7 Zack’s Equity Research. Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer. Yahoo Finance Jan. 21, 2026.
8 Ibid.
9 Liu A. With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine. Fierce Pharma Apr. 6, 2026.
10 Ibid.
11 Zack’s Equity Research. Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer. Yahoo Finance Jan. 21, 2026.
12 Liu A. With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine. Fierce Pharma Apr. 6, 2026.
One Response
Your tax dollars hard at work. This is why everyone should stop with the consumerist model and pay less taxes instead. Nobody would fund these companies voluntarily out of their own pockets for these products and research. These companies exist exclusively due to the various forms of taxpayer funding, which they enjoy direct and indirect funding avenues.
In the real world people are talking about life extension using C-60 in combination with stem cells. No vaccines required. Cut these executives power off. Fire everyone. Send them home forever. The public ‘needs’ more vaccine research like one ‘needs’ to drink poison by the gallon. There is no greater objection than absence. Ignore those fools.